The bill requires the Executive Office of Health and Human Services to submit a quarterly report detailing the projected total costs for pharmaceutical pipeline drugs anticipated to be available for use within the next fiscal year. Specifically, it highlights that 67 new pipeline market entries are expected to be available between July 1, 2025, and June 30, 2026, with an estimated expenditure of approximately $19.9 million for all MassHealth members, which includes those enrolled in managed care. This marks an increase from a previous estimate of $19.5 million based on 65 pipeline entries, with high-cost cell and gene therapies being significant contributors to the projected spending. Additionally, the bill includes a new contact email for inquiries related to the report, specifically Sarah.Nordberg@mass.gov. This change aims to streamline communication regarding the report and its findings.